title: Mesalazine-induced aplastic anemia.
authors.forename: Ari
authors.initials: A
authors.lastname: Wiesen
authors.forename: Jonathan
authors.initials: J
authors.lastname: Wiesen
authors.forename: Sewanti
authors.initials: S
authors.lastname: Limaye
authors.forename: Neeraj
authors.initials: N
authors.lastname: Kaushik
mesh_terms: D000741:Anemia, Aplastic / Q000139:chemically induced* / Q000175:diagnosis / Q000188:drug therapy; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000009:adverse effects* / Q000627:therapeutic use; D000961:Antilymphocyte Serum / Q000627:therapeutic use; D003424:Crohn Disease / Q000188:drug therapy; D003937:Diagnosis, Differential; D004359:Drug Therapy, Combination; D005260:Female; D000069585:Filgrastim; D016179:Granulocyte Colony-Stimulating Factor / Q000627:therapeutic use; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D019804:Mesalamine / Q000009:adverse effects* / Q000627:therapeutic use; D008875:Middle Aged; D011994:Recombinant Proteins; D012307:Risk Factors
chemical_list: D000894:Anti-Inflammatory Agents, Non-Steroidal; D000961:Antilymphocyte Serum; D007166:Immunosuppressive Agents; D011994:Recombinant Proteins; D016179:Granulocyte Colony-Stimulating Factor; D019804:Mesalamine; D000069585:Filgrastim